The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.
All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.
Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.
The treated patient achieved an overall partial response of 72% in tumor regression.
The chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.